S. R. Leist

Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination

This study compares IgG antibody responses from SARS-CoV-2 infection, vaccination, and hybrid immunity, finding that hybrid immunity retains the imprint of the initial exposure and enhances antibody breadth and affinity.

Efficacy of Host Cell Serine Protease Inhibitor MM3122 against SARS-CoV-2 for Treatment and Prevention of COVID-19

This paper demonstrates that MM3122, a host cell serine protease inhibitor, effectively inhibits SARS-CoV-2 replication and reduces disease severity in mice, both prophylactically and therapeutically.

Host genetic variation guides hepacivirus clearance, chronicity, and liver fibrosis in mice

The paper infects diverse mouse strains with a hepacivirus and shows host genetic variation influences viral clearance, chronicity, and liver fibrosis outcomes.

Extremely potent pan-sarbecovirus neutralizing antibodies generated by immunization of macaques with an AS03-adjuvanted monovalent subunit vaccine against SARS-CoV-2

This study identifies potent pan-sarbecovirus neutralizing antibodies from vaccinated macaques, showing broad neutralization against SARS-CoV-2 variants and related viruses.

Fc mediated pan-sarbecovirus protection after alphavirus vector vaccination

This study shows that non-neutralizing antibodies targeting FcR4 and spike S2 provide cross-protection against sarbecoviruses after alphavirus vector vaccination.

A Multitrait Locus Regulates Sarbecovirus Pathogenesis

The paper identifies a multitrait locus on mouse Chromosome 9 that regulates SARS-CoV, SARS-CoV-2, and bat sarbecovirus disease severity, with candidate genes CCR9 and CXCR6.

A model of persistent post SARS-CoV-2 induced lung disease for target identification and testing of therapeutic strategies

This paper develops a murine model of persistent post-SARS-CoV-2 lung disease to identify therapeutic targets and test interventions for PASC.

Protective efficacy of rhesus adenovirus COVID-19 vaccines against mouse-adapted SARS-CoV-2

This study evaluates the protective efficacy of rhesus adenovirus serotype 52 vaccines against a mouse-adapted SARS-CoV-2 strain, showing robust antibody responses and protection against viral replication and disease.

Common Mechanism of SARS-CoV and SARS-CoV-2 Pathogenesis across Species

The paper identifies host susceptibility loci for SARS-CoV and SARS-CoV-2 using GWAS and Collaborative Cross datasets, validating CCR9 as a key regulator of severe disease outcomes across species.

Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice

This study shows chimeric spike mRNA vaccines protect mice against multiple Sarbecovirus strains, including variants and zoonotic viruses, better than standard SARS-CoV-2 vaccines.

Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice

This study evaluates combination therapies of remdesivir and monoclonal antibodies for SARS-CoV-2 and its B.1.351 variant in mice, showing improved outcomes with the antibody combination.

SARS-CoV-2 D614G Variant Exhibits Enhanced Replication ex vivo and Earlier Transmission in vivo

This study shows the SARS-CoV-2 D614G variant replicates more efficiently and transmits faster in hamsters than the wildtype virus.

Baseline T cell immune phenotypes predict virologic and disease control upon SARS-CoV infection

The paper shows that baseline T cell immune signatures in mice predict virologic and disease outcomes upon SARS-CoV infection.

Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection in vivo

This study evaluates the in vivo protective efficacy of SARS-CoV-2 monoclonal antibodies, finding that in vitro potency does not always predict in vivo activity and that effector function and combinations are critical for protection.

Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2

This study designs SARS-CoV-2 nanoparticle vaccines that induce strong neutralizing antibodies in mice, with higher titers and lower doses than existing trimer vaccines.

A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine

This paper evaluates an inactivated Newcastle disease virus expressing the SARS-CoV-2 spike protein as a cost-effective vaccine, showing immunogenicity and protective efficacy in animal models.

Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate

This paper describes NDV vector vaccines expressing SARS-CoV-2 spike protein that protect mice from viral challenge and can be produced cost-effectively in chicken eggs.

SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness

This paper describes the development of an mRNA vaccine (mRNA-1273) against SARS-CoV-2, showing it induces neutralizing antibodies and CD8 T cell responses and protects mice from infection.

Rapid selection of a human monoclonal antibody that potently neutralizes SARS-CoV-2 in two animal models

This study rapidly identifies a potent human monoclonal antibody against SARS-CoV-2 that neutralizes the virus in animal models and shows promise for therapeutic use.

A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures

This paper develops a mouse-adapted SARS-CoV-2 model to evaluate medical countermeasures, showing age-related disease severity and the efficacy of IFN lambda-1a.

Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice.

This study shows remdesivir effectively inhibits SARS-CoV-2 in human cells and mice, reducing viral load and improving lung function.

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 and multiple endemic, epidemic and bat coronavirus

This study demonstrates that the antiviral NHC/EIDD-2801 inhibits SARS-CoV-2 and multiple coronaviruses, showing therapeutic efficacy and oral bioavailability in mice.

Combination attenuation offers strategy for live-attenuated coronavirus vaccines

This study shows combining NSP16 mutation with other attenuating mutations creates a safe and effective live-attenuated coronavirus vaccine that works in aged mice and against heterologous challenges.

MERS-CoV NSP16 necessary for IFN resistance and viral pathogenesis

This study shows that disrupting MERS-CoV NSP16's 2O methyl-transferase activity attenuates viral pathogenesis and provides a live attenuated vaccine platform.